Ventricular Function, Left

"Ventricular Function, Left" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The hemodynamic and electrophysiological action of the left HEART VENTRICLE. Its measurement is an important aspect of the clinical evaluation of patients with heart disease to determine the effects of the disease on cardiac performance.

Descriptor ID	D016277
MeSH Number(s)	G09.330.955.800
Concept/Terms	Ventricular Function, Left Ventricular Function, Left Left Ventricular Function Function, Left Ventricular Functions, Left Ventricular Left Ventricular Functions Ventricular Functions, Left

Below are MeSH descriptors whose meaning is more general than "Ventricular Function, Left".

Biological Sciences [G]
Circulatory and Respiratory Physiological Phenomena [G09]
Cardiovascular Physiological Phenomena [G09.330]
Ventricular Function [G09.330.955]
Ventricular Function, Left [G09.330.955.800]

Below are MeSH descriptors whose meaning is related to "Ventricular Function, Left".

Below are MeSH descriptors whose meaning is more specific than "Ventricular Function, Left".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Ventricular Function, Left" by people in this website by year, and whether "Ventricular Function, Left" was a major or minor topic of these publications.

Bar chart showing 178 publications over 29 distinct years, with a maximum of 13 publications in 2013 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	2	2	4
1998	2	1	3
1999	0	1	1
2000	1	1	2
2001	2	2	4
2002	2	3	5
2003	2	4	6
2004	2	2	4
2005	2	1	3
2006	0	4	4
2007	1	2	3
2008	2	2	4
2009	1	6	7
2010	3	3	6
2011	1	1	2
2012	2	3	5
2013	11	2	13
2014	5	3	8
2015	6	2	8
2016	3	1	4
2017	1	3	4
2018	6	3	9
2019	6	6	12
2020	7	6	13
2021	1	5	6
2022	2	8	10
2023	2	7	9
2024	4	6	10
2025	4	5	9

Below are the most recent publications written about "Ventricular Function, Left" by people in Profiles.

Kim JH, Kiernan MS. Predictors of Left Ventricular Reverse Remodeling in Heart Failure with Reduced Ejection Fraction. Curr Heart Fail Rep. 2025 Nov 14; 22(1):39.

View in: PubMed
Wang X, Pabon MA, Makuvire TT, Maimaiti R, Abraham TP, Barriales-Villa R, Claggett BL, Coats CJ, Maron MS, Masri A, Meder B, Nassif ME, Olivotto I, Owens AT, Saberi S, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Solomon SD, Hegde SM. Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM. Circ Heart Fail. 2026 Jan; 19(1):e013918.

View in: PubMed
Antiochos P, Ge Y, Jerosch-Herold M, David LP, Heydari B, Kolm P, Kim DY, van der Geest RJ, Watkins H, Desai MY, Ho CY, Dolman SF, Desvigne-Nickens P, Maron MS, Schulz-Menger J, Piechnik SK, Appelbaum E, Weintraub WS, Neubauer S, Kramer CM, Kwong RY. Myocardial Entropy and Risk Predictors in Hypertrophic Cardiomyopathy: An Analysis From the NHLBI HCM Registry. Circ Cardiovasc Imaging. 2025 Nov; 18(11):e018031.

View in: PubMed
Hegde SM, Wang X, Garcia-Pavia P, Getchevski S, Masri A, Merkely B, Nassif ME, Pe?a-Pe?a ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Lakdawala NK, Mann A, Maron MS, Nair A, Poulsen SH, Reant P, Schulze PC, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Solomon SD. Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM. J Am Coll Cardiol. 2025 Dec 16; 86(24):2452-2467.

View in: PubMed
Mihos CG, Liu JE, Anderson KM, Pernetz MA, O'Driscoll JM, Aurigemma GP, Ujueta F, Wessly P. Speckle-Tracking Strain Echocardiography for the Assessment of Left Ventricular Structure and Function: A Scientific Statement From the American Heart Association. Circulation. 2025 Sep 09; 152(10):e96-e109.

View in: PubMed
Saberi S, Abraham TP, Choudhury L, Barriales-Villa R, Elliott PM, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats CJ, Fifer MA, Sherrid MV, Solomon SD, Watkins H, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Maron MS, Masri A. Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM. JACC Heart Fail. 2025 Aug; 13(8):102496.

View in: PubMed
Davis BJ, Volk H, Nguyen O, Kamna D, Chen H, Barriales-Villa R, Garcia-Pavia P, Olivotto I, Owens AT, Coats CJ, Abraham TP, Solomon SD, Maron MS, Masri A. Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2025 Mar 18; 14(6):e038758.

View in: PubMed
Henry A, Mo X, Finan C, Chaffin MD, Speed D, Issa H, Denaxas S, Ware JS, Zheng SL, Malarstig A, Gratton J, Bond I, Roselli C, Miller D, Chopade S, Schmidt AF, Abner E, Adams L, Andersson C, Aragam KG, ?rnl?v J, Asselin G, Raja AA, Backman JD, Bartz TM, Biddinger KJ, Biggs ML, Bloom HL, Boersma E, Brandimarto J, Brown MR, Brunak S, Bruun MT, Buckbinder L, Bundgaard H, Carey DJ, Chasman DI, Chen X, Cook JP, Czuba T, de Denus S, Dehghan A, Delgado GE, Doney AS, D?rr M, Dowsett J, Dudley SC, Engstr?m G, Erikstrup C, Esko T, Farber-Eger EH, Felix SB, Finer S, Ford I, Ghanbari M, Ghasemi S, Ghouse J, Giedraitis V, Giulianini F, Gottdiener JS, Gross S, Gu?bjartsson DF, Gui H, Gutmann R, H?gg S, Haggerty CM, Hedman ?K, Helgadottir A, Hemingway H, Hillege H, Hyde CL, Aagaard Jensen B, Jukema JW, Kardys I, Karra R, Kavousi M, Kizer JR, Kleber ME, K?ber L, Koekemoer A, Kuchenbaecker K, Lai YP, Lanfear D, Langenberg C, Lin H, Lind L, Lindgren CM, Liu PP, London B, Lowery BD, Luan J, Lubitz SA, Magnusson P, Margulies KB, Marston NA, Martin H, M?rz W, Melander O, Mordi IR, Morley MP, Morris AP, Morrison AC, Morton L, Nagle MW, Nelson CP, Niessner A, Niiranen T, Noordam R, Nowak C, O'Donoghue ML, Ostrowski SR, Owens AT, Palmer CNA, Par? G, Pedersen OB, Perola M, Pigeyre M, Psaty BM, Rice KM, Ridker PM, Romaine SPR, Rotter JI, Ruff CT, Sabatine MS, Sallah N, Salomaa V, Sattar N, Shalaby AA, Shekhar A, Smelser DT, Smith NL, S?rensen E, Srinivasan S, Stefansson K, Sveinbj?rnsson G, Svensson P, Tammesoo ML, Tardif JC, Teder-Laving M, Teumer A, Thorgeirsson G, Thorsteinsdottir U, Torp-Pedersen C, Tragante V, Trompet S, Uitterlinden AG, Ullum H, van der Harst P, van Heel D, van Setten J, van Vugt M, Veluchamy A, Verschuuren M, Verweij N, Vissing CR, V?lker U, Voors AA, Wallentin L, Wang Y, Weeke PE, Wiggins KL, Williams LK, Yang Y, Yu B, Zannad F, Zheng C, Asselbergs FW, Cappola TP, Dub? MP, Dunn ME, Lang CC, Samani NJ, Shah S, Vasan RS, Smith JG, Holm H, Shah S, Ellinor PT, Hingorani AD, Wells Q, Lumbers RT. Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes. Nat Genet. 2025 Apr; 57(4):815-828.

View in: PubMed
Massera D, Sherrid MV, Adlestein E, Bokhari N, Alvarez IC, Wu WY, Reuter MC, Maron MS, Maron BJ, Rowin EJ. Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5?Years. J Am Heart Assoc. 2025 Jan 21; 14(2):e037639.

View in: PubMed
Hegde SM, Claggett BL, Wang X, Jering K, Prasad N, Roshanali F, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Cardim N, Coats CJ, Kramer CM, Maron MS, Michels M, Olivotto I, Saberi S, Jacoby DL, Heitner SB, Kupfer S, Meng L, Wohltman A, Malik FI, Solomon SD. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024 Nov 05; 84(19):1789-1802.

View in: PubMed

People

Explore

Similar Concepts

Top Journals